John R. Hornick - Concepedia

Author

John R. Hornick

Washington University in St. Louis

Also Known As

Dai Chung, J.R. Hornick, John Hornick, John R Hornick, John R. Hornick

Publications

725

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis University of Bari Aldo Moro Alvin J. Siteman Cancer Center

About

John R. Hornick is an author at Washington University in St. Louis specializing in medicine, molecular pharmacology, and small molecules.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	373
2	Natural Sciences	1	1	34
3	Public Health	1	1	164
4	Biochemistry	1	1	34
5	Biology	1	1	164

John R. Hornick

Publications

626

Citations

H-Index

Page 1

	Year	Citations
Distribution of Type A Spermatogonia in the Mouse Is Not Random1 Hélio Chiarini‐Garcia, John R. Hornick, Michael D. Griswold, Biology of Reproduction SpermatogenesisFertilityGeneticsSpermatogenic CycleSemen Analysis	2001	164
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma Andrea Wang‐Gillam, Stacey M. Plambeck-Suess, Peter S. Goedegebuure, Investigational New Drugs Pancreatic CancerFront-line TherapyGastrointestinal OncologyMedicinePathology	2012	95
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine John R. Hornick, Jinbin Xu, Suwanna Vangveravong, Molecular Cancer	2010	78
Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer John R. Hornick, Suwanna Vangveravong, Dirk Spitzer, Journal of Experimental & Clinical Cancer Research	2012	78
Use of Multifunctional Sigma-2 Receptor Ligand Conjugates to Trigger Cancer-Selective Cell Death Signaling Dirk Spitzer, Peter O. Simon, Hiroyuki Kashiwagi, Cancer Research NanotherapeuticsApoptosisImmunologyCell DeathImmunotherapeutics	2011	50
Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV‐134 Yassar M. Hashim, Dirk Spitzer, Suwanna Vangveravong, Molecular Oncology	2014	42
Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer Maria Laura Pati, John R. Hornick, Mauro Niso, BMC Cancer	2017	39
Fluorescent Derivatives of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a Tool for Uptake and Cellular Localization Studies in Pancreatic Tumor Cells Carmen Abate, John R. Hornick, Dirk Spitzer, Journal of Medicinal Chemistry Pancreatic Tumor CellsCellular PharmacologyCancer BiologyTumor BiologyMolecular Pharmacology	2011	34
A telephone call 1 week after hospitalization can identify risk factors for vascular surgery readmission John R. Hornick, Joshua Balderman, Ronnie L. Eugea, Journal of Vascular Surgery Cardiovascular DiseasePatient SafetyVascular Surgery ReadmissionVascular SurgeryOutcomes Research	2016	30
Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line Elizabeth Chang, James Donahue, Anna Smith, Journal of Thoracic and Cardiovascular Surgery	2010	16

Page 1